News
Data sets up 2021 filings for Gilead's twice-a-year HIV drug...
Gilead Sciences has the data it was hoping for in a pivotal trial of lenacapavir, an HIV drug that only needs to be dosed by subcutaneous injection every six months, keeping it on course fo